​

Reviva Pharmaceuticals (RVPH) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

RVPH Stock Rating

Reviva Pharmaceuticals stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

RVPH Price Target Upside V Benchmarks

TypeNameUpside
StockReviva Pharmaceuticals-
SectorHealthcare Stocks 13.55%
IndustryBiotech Stocks 49.00%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.44$0.44$0.44
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 2524---6
Aug, 2533---6
Jul, 2533---6
Jun, 2533---6
May, 2533---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 18, 2025Roth CapitalBuyBuyhold
Aug 15, 2025CitigroupBuyBuyhold
Sep 23, 2024EF HuttonBuyinitialise
Jun 11, 2024H.C. WainwrightBuyBuyhold
Jan 24, 2022H.C. WainwrightBuyinitialise

Financial Forecast

EPS Forecast

$-2 $-1 $0 $1 $2 $3 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.25$-1.65-----
Avg Forecast$-1.09$-1.60$-0.98$-0.84$-0.83$0.78$2.08
High Forecast$-1.09$-1.48$-0.96$-0.76$-0.48$0.98$2.08
Low Forecast$-1.09$-1.71$-1.01$-0.91$-1.30$0.58$2.08
Surprise %14.68%3.13%-----

Revenue Forecast

$135M $153M $171M $189M $207M $225M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-------
Avg Forecast----$220.44M$137.30M$137.99M
High Forecast----$220.44M$137.30M$137.99M
Low Forecast----$220.44M$137.30M$137.99M
Surprise %-------

Net Income Forecast

$-40T $-31T $-22T $-13T $-4T $5T Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-24.34M$-39.26T-----
Avg Forecast$-21.27M$-39.26M$-23.52M$-19.82M$-21.23M$18.56M$49.50M
High Forecast$-21.27M$-35.13M$-22.92M$-18.04M$-11.50M$23.33M$49.50M
Low Forecast$-21.27M$-40.78M$-24.13M$-21.59M$-30.96M$13.80M$49.50M
Surprise %14.41%99999900.00%-----

RVPH Forecast FAQ

Is Reviva Pharmaceuticals stock a buy?

Reviva Pharmaceuticals stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Reviva Pharmaceuticals is a favorable investment for most analysts.

What is Reviva Pharmaceuticals's price target?

Reviva Pharmaceuticals's price target, set by 7 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $0.44.

How does Reviva Pharmaceuticals stock forecast compare to its benchmarks?

Reviva Pharmaceuticals's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (13.55%) and underperforming the biotech stocks industry (49.00%).

What is the breakdown of analyst ratings for Reviva Pharmaceuticals over the past three months?

  • September 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Reviva Pharmaceuticals’s EPS forecast?

Reviva Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.98, marking a -40.61% decrease from the reported $-1.65 in 2023. Estimates for the following years are $-0.84 in 2025, $-0.83 in 2026, $0.78 in 2027, and $2.08 in 2028.

What is Reviva Pharmaceuticals’s revenue forecast?

Reviva Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2024 is $0, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $0, followed by $220.44M for 2026, $137.3M for 2027, and $137.99M for 2028.

What is Reviva Pharmaceuticals’s net income forecast?

Reviva Pharmaceuticals's net income forecast for the fiscal year ending in December 2024 stands at $-23.522M, representing a -100.00% decrease from the reported $-39.261T in 2023. Projections indicate $-19.816M in 2025, $-21.226M in 2026, $18.56M in 2027, and $49.5M in 2028.